Off-Label Use: US FDA Backs Away From ‘Totality Of Evidence’ Standard In Proposed Reg
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
Future guidances may address information on healthcare sites and individual influencers and endorsers. ‘It is a difficult time to make any predictions about the timing of guidance,’ but the agency is looking at these issues, CDER deputy center director Grail Sipes tells FDLI conference.
Stacy Cline Amin says authorizing or licensing a COVID-19 vaccine is ‘perhaps the most consequential action the agency will ever take.’ Speaking at FDLI conference, she notes that standards for vaccine EUA will be higher than what has been required for therapeutics.